Skip to main content

Table 6 Correlations between the optimal thresholds of TILs and pCR in neoadjuvant treated TNBCs

From: Predictive value of tumor-infiltrating lymphocytes to pathological complete response in neoadjuvant treated triple-negative breast cancers

Variables Univariate analysis Multivariate analysis
OR 95% CI P-value OR 95% CI P-value
ITILs (< 10% vs. ≥10%) 2.62 1.38–4.97 0.003* 1.97 0.98-3.98 0.06
STILs (< 20% vs. ≥20%) 2.87 1.51–5.47 0.001* 2.85 1.38-5.90 0.005*
Age(years) (< 50 vs. ≥50) 0.51 0.27–0.95 0.04* 0.70 0.33-1.45 0.33
Histological grade (2 vs. 3) 2.74 1.11–6.80 0.03* 1.02 0.34-3.10 0.97
Tumor size (cm) (≤2 vs. 2–5 vs. > 5) 1.30 0.74–2.29 0.37 1.12 0.58–2.14 0.74
Nodal status (positive vs. negative) 0.93 0.48–1.81 0.84 1.76 0.82–3.79 0.15
LVI (positive vs. negative) 0.06 0.01–0.26 0.0001* 0.05 0.01-0.25 0.0001*
Ki-67 index 2.47 1.17–5.24 0.02* 1.03 1.01-1.04 0.004*
NAC (Anthracycline + paclitaxel vs. paclitaxel + platinum) 0.83 0.37–1.87 0.65 0.99 0.49–2.00 0.97
  1. Abbreviations: pCR pathological complete response, TNBCs triple-negative breast cancers, sTILs stromal tumor-infiltrating lymphocytes, iTILs intratumoral tumor-infiltrating lymphocytes, LVI lymphovascular invasion, NAC neoadjuvant chemotherapy, OR odds ratio, 95% CI 95% confidence interval
  2. *The P value is significant